These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36114575)

  • 1. Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.
    Rai A; Yelamanchi SD; Radotra BD; Gupta SK; Mukherjee KK; Tripathi M; Chhabra R; Ahuja CK; Kumar N; Pandey A; Korbonits M; Dutta P; Gaston-Massuet C
    Acta Neuropathol Commun; 2022 Sep; 10(1):138. PubMed ID: 36114575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
    Li J; Wen S; Li B; Li N; Zhan X
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.
    Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J
    Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
    Wen S; Li J; Yang J; Li B; Li N; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
    Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
    Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
    Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
    Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
    Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
    J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
    Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
    Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
    Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
    Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
    Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
    Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
    Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
    Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
    Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
    Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying prognostic predictors for postoperative pituitary neuroendocrine tumour recurrence: an integrated clinical, radiological, and immunohistochemistry assessment.
    Chen CY; Chen JS; Chen YS; Yin CH; Jan CI; Hsu SH; Yang YC; Liao WC
    Br J Neurosurg; 2024 Aug; ():1-8. PubMed ID: 39105524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
    Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
    Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.